Artia Global Partners LP Takes Position in United Therapeutics Corporation $UTHR

Key Points

• Artia Global Partners initiated a 5,000-share position in United Therapeutics during the second quarter, valued at approximately $2.7 million. Institutional investors collectively own 94.08% of the company.
• United Therapeutics beat quarterly earnings expectations with $7.27 in EPS versus the $6.86 consensus estimate, although revenue of $783.3 million missed estimates and declined 1.9% year over year.
• The stock opened at $516.68, while analysts maintain a “Moderate Buy” consensus and an average price target of $646. Recent insider selling totaled 424,075 shares worth about $227.7 million over three months.

Artia Global Partners LP bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,000 shares of the biotechnology company's stock, valued at approximately $2,709,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of United Therapeutics in the second quarter valued at about $2,868,735,000. Wellington Management Group LLP grew its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the second quarter valued at $450,140,000. Norges Bank purchased a new position in United Therapeutics during the 4th quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC increased its stake in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 0.4%

Shares of UTHR opened at $516.68 on Thursday. The company's fifty day moving average is $531.06 and its two-hundred day moving average is $538.56. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The firm has a market cap of $22.16 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm posted $6.41 earnings per share. The firm's revenue was down 1.9% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business's stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $22,185,323.93. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 424,075 shares of company stock worth $227,683,710 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source